SAN DIEGO, May 3, 2016 /PRNewswire/ -- Sequenom, Inc.,
(NASDAQ: SQNM), a life sciences company committed to enabling
healthier lives through the development of innovative products and
services, today announced that it has entered into agreements with
Blue Cross and Blue Shield of Georgia, Inc. (effective 4/11/16), Anthem Blue
Cross and Blue Shield Health Plans for Indiana, Kentucky, Missouri, Ohio and Wisconsin (effective 5/15), and Anthem Blue
Cross and Blue Shield in Virginia
(effective 5/23/16).
The agreements provide in-network coverage for Sequenom
Laboratories™' noninvasive prenatal tests for both high and
average-risk pregnancies to Anthem's members in those states.
The Georgia agreement does not
include HMO plans, and the Virginia agreement does not include
HealthKeepers products.
"Becoming an in-network provider with leading health insurers,
particularly for average risk pregnancies, is a critical component
of our commercialization plan," said Dirk
van den Boom, Ph.D., President and CEO of Sequenom.
"The addition of these seven states to our Anthem Blue Cross and
Blue Shield relationship represents meaningful progress in our
efforts to bring the benefits of noninvasive prenatal testing to
women throughout the United
States."
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a pioneering genetic testing
company dedicated to women's health through the development of
innovative products and services. The Company serves patients
and physicians by providing early patient management
information. For more information, visit
www.sequenom.com.
About Sequenom Laboratories
Sequenom Laboratories, a CAP-accredited and CLIA-certified
molecular diagnostics laboratory, has developed a broad range of
laboratory tests, with a focus principally on prenatal care.
Branded under the names HerediT®, HerediT®
UNIVERSAL, MaterniT® GENOME, MaterniT® 21
PLUS, NextView®, SensiGene® and VisibiliT™,
these molecular genetic laboratory-developed tests provide early
patient management information for obstetricians, geneticists, and
maternal fetal medicine specialists. Sequenom Laboratories is
changing the landscape in genetic diagnostics using proprietary
cutting edge technologies. Visit www.laboratories.sequenom.com and
follow @SequenomLabs.
SEQUENOM®, HerediT®,
MaterniT®, NextView®, SensiGene®,
VisibiliT™ and Sequenom Laboratories™ are
trademarks of Sequenom, Inc. All other trademarks and service
marks are the property of their respective owners.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 including statements regarding the development of
innovative products and services and the ability to bring the
benefits of noninvasive prenatal testing to women throughout
the United States. Because such statements are subject to
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking
statements. Risks are described more fully in the Company's
filings with the Securities and Exchange Commission, including
without limitation the Company's most recent Annual Report on Form
10-K and other documents subsequently filed with or furnished to
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. The Company undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Logo -
http://photos.prnewswire.com/prnh/20160225/337675LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sequenom-announces-in-network-contracts-with-anthem-blue-cross-and-blue-shield-plans-for-georgia-indiana-kentucky-missouri-ohio-virginia-and-wisconsin-300262315.html
SOURCE Sequenom, Inc.